biostudies-literatureJeon JNational Institute of Environmental Health SciencesNational Institute of Neurological Disorders and StrokeCollege of Liberal Arts and Sciences - Department of ChemistryNational Institutes of Health National Cancer InstituteNIA NIH HHSEmory College of Arts and Sciences, Emory UniversityNIEHS NIH HHSNCI NIH HHSNINDS NIH HHSNational Institute on Aging100183https://www.ebi.ac.uk/biostudies/studies/S-EPMC12923290biostudies-literatureUnknown53(11)Drug monitoring is an essential component of precision therapeutics, yet existing data bases to support therapeutic monitoring are limited to data curated from the scientific literature or predicted in silico. We used human liver S9 fraction to generate metabolites from 1114 therapeutic drugs spanning diverse drug classes. Metabolites were analyzed by liquid chromatography-high-resolution mass spectrometry, annotated through differential analysis of preincubation and postincubation samples, curated by comparison to predicted metabolites from BioTransformer 3.0, and compiled into a human liver pharmaceutical metabolite resource, named "Pharmaceutical Metabolite Data Base (PharmMet DB)." Liquid chromatography-high-resolution mass spectrometry showed heterogeneity in product generation, with Drug metabolism and disposition: the biological fate of chemicalsPharmaceutical Metabolite Data Base, PharmMet DB: Reference data base for drug metabolites generated by human liver S9 fraction.PMC12923290U01 AG088658R01 CA264519R01 NS130713R01 ES031980R01 AG085279R21 AG080247P30 ES019776Morgan ETLee CMJones DPGo YMJarrell ZRWeinberg JLiu KHSinger GJeon JfalsePharmaceutical Metabolite Data Base, PharmMet DB: Reference data base for drug metabolites generated by human liver S9 fraction.Drug monitoring is an essential component of precision therapeutics, yet existing data bases to support therapeutic monitoring are limited to data curated from the scientific literature or predicted in silico. We used human liver S9 fraction to generate metabolites from 1114 therapeutic drugs spanning diverse drug classes. Metabolites were analyzed by liquid chromatography-high-resolution mass spectrometry, annotated through differential analysis of preincubation and postincubation samples, curated by comparison to predicted metabolites from BioTransformer 3.0, and compiled into a human liver pharmaceutical metabolite resource, named "Pharmaceutical Metabolite Data Base (PharmMet DB)." Liquid chromatography-high-resolution mass spectrometry showed heterogeneity in product generation, with 2025-01-01T00:00:00Z2025 Nov2026-07-09T11:40:24.668Z2026-07-09T10:54:37.351ZS-EPMC129232904118751410.1016/j.dmd.2025.100183